-
Treating Colorectal Cancer: Overview of MRD Testing and ctDNA
Dr. Marshall and Dr. Weinberg and other oncologists, provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.
Category: News
-
Fight CRC Raises Colorectal Cancer Awareness on National Mall
To celebrate National Colorectal Cancer Awareness Month, volunteers for the advocacy organization Fight CRC planted 27,400 flags across the National Mall to raise awareness about early-onset colorectal cancer rates Mar. 9.
Category: News
-
Molecular Profiling Improves Outcomes in Biliary Tract Cancer
Research by Dr. Aiwu Ruth He shows patients with biliary cancer who undergo molecular profiling appear to survive significantly longer when compared with those who do not.
Category: News
-
GI Cancer Chronicles: Meet Dr. Marshall
Meet Dr. Marshall, a medical oncologist with over 30 years of experience treating patients with gastrointestinal cancer. In his years of practice, he has dedicated himself to improving the lives of patients through research, advocacy, and innovative care.
Category: News
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
Learn more about exciting pancreatic research being conducted by Drs. Louis Weiner, Allison Fitzgerald, and Benjamin Weinberg.
Category: News
-
Report: Cancer Incidence Rising in Adults Younger Than 50
Dr. John Marshall shares his observations about the rise in early-onset Colorectal Cancer.
Category: News
-
Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCC
Aiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
Category: News
-
People who got colon cancer in their 20s or 30s describe what it was like and the signs that were ignored
Dr. Marshall is interviewed discussing symptoms of colorectal cancer
Category: News
-
Ruesch Center Symposium Focuses on Early-Onset GI Cancer
John Marshall, MD, director of the Ruesch Center, defined the focus for the scientific briefing portion of this year’s symposium: young people getting GI cancers at an alarming rate.
Category: News
-
FDA Approval of Fruquintinib Expands Later-Line Treatment Options in mCRC
John L. Marshall, MD, sheds light on the significance of the FDA approval of fruquintinib for patients with heavily pretreated metastatic colorectal cancer and discusses the efficacy and safety data from the FRESCO and FRESCO-2 trials that supported the decision in this population.
Category: News